title: Inhaled mannitol for the treatment of cystic fibrosis.
abstract: Inhaled dry powder mannitol is well established for use in bronchial provocation testing. Inhaled mannitol also increases mucociliary clearance, and therefore could have a role in treating chronic suppurative lung disease. There have been a number of studies in cystic fibrosis and bronchiectasis. An international Phase III trial has just been published that suggests the use of regular inhaled mannitol increases lung function and reduces exacerbation frequency in cystic fibrosis. Inhaled mannitol exerts its effects in a number of ways, most importantly like hypertonic saline, setting up an osmotic gradient so water flows into the airway lumen, increasing mucus hydration and mucociliary clearance. Its formulation as a dry powder makes it quick and convenient to take.
authors.affiliation: Department of Cystic Fibrosis, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK.
authors.forename: Katharine
authors.initials: K
authors.lastname: Hurt
authors.forename: Diana
authors.initials: D
authors.lastname: Bilton
mesh_terms: D000280:Administration, Inhalation; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D005100:Expectorants / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008353:Mannitol / Q000008:administration & dosage* / Q000009:adverse effects; D009079:Mucociliary Clearance / Q000187:drug effects; D011208:Powders; D016896:Treatment Outcome
chemical_list: D005100:Expectorants; D011208:Powders; D008353:Mannitol